Mohamed Sorror, MD
Enriched profileProfessor, Clinical Research Division, Fred Hutchinson Cancer Research Center · Fred Hutchinson Cancer Research Center
Mohamed Sorror is Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center at Fred Hutchinson Cancer Research Center. OpenAlex indexes 325 publications with 18,558 citations (h-index 61); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 23 Oct 2026
Mohamed Sorror, M.D., M.SC., is Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center. The public record shows 325 publications with 18,558 citations (h-index 61), centered on Hematopoietic Stem Cell Transplantation, Transplantation: Methods and Outcomes, Renal Transplantation Outcomes and Treatments. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 3 companies, 3 NIH-funded awards (2007–2024).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Hematopoietic Stem Cell Transplantation
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 131.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
Sponsor: Center for International Blood and Marrow Transplant Research
- Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI
Sponsor: Fred Hutchinson Cancer Center
Industry payments
Updated 23 Oct 2026
3 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- National Marrow Donor ProgramProgram year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- National Marrow Donor ProgramProgram year20242 payments
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Osmotically acting laxatives100%Magnesium Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
3 NIH research awards on record, funded 2007–2024 per NIH RePORTER. The latest:
- Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality
Fred Hutchinson Cancer Center
FY2024$809,535R01CA227092 - Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality
Fred Hutchinson Cancer Center
FY2023$855,411R01CA227092 - Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality
Fred Hutchinson Cancer Center
FY2021$650,164R01CA227092
Congress activity
Updated 23 Oct 2026
28 congress contributions (2006–2025) across ASCO, ASH per OpenAlex. The most recent:
- Factors associated with frailty in vulnerable hematopoietic cell transplantation candidates.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01
- 02Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationArticle1,493 citations2010
- 03Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell TransplantationArticle632 citations2011
- 04Cord-Blood Transplantation in Patients with Minimal Residual DiseaseArticle445 citations2016
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mohamed-sorror-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
fredhutch.org/en/people/s/mohamed-sorror.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fredhutch.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mazyar Shadman, MD, MPH
Fred Hutchinson Cancer Research Center
Bart Scott, MD
Fred Hutchinson Cancer Research Center
Joshua Schiffer, MD
Fred Hutchinson Cancer Research Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center